Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 3/20 | 0.54 |
| ▸ | NSD2 | O96028 | 12/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449177 | 0.91 | CCR8 (0.51) | CCR8NSD2BRD4TNFNOD2 | |
| SCHEMBL4444987 | 0.86 | NSD2 (0.66) | CCR8NSD2FABP4LMNA | |
| SCHEMBL4446946 | 0.85 | CCR8 (0.58) | CCR8NSD2FABP4 | |
| SCHEMBL4444940 | 0.83 | FABP4 (0.60) | CCR8NSD2FABP4 | |
| SCHEMBL4443344 | 0.82 | LMNA (0.55) | CCR8NSD2LMNASMN1; SMN2 | |
| SCHEMBL4454907 | 0.82 | CCR8 (0.51) | CCR8NSD2FABP4 | |
| SCHEMBL4449304 | 0.82 | CCR8 (0.53) | CCR8NSD2 | |
| SCHEMBL4446944 | 0.82 | NSD2 (0.64) | CCR8NSD2LMNA | |
| SCHEMBL4448416 | 0.82 | NSD2 (0.54) | CCR8NSD2 | |
| SCHEMBL4453218 | 0.81 | CCR8 (0.55) | CCR8NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547716-B2 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1402890-B1 | SULFONAMIDE DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20040234622-A1 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1402890-A1 | SULFONAMIDE DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | PCNA, TOP2A, DDB1 | CCR8 2931/4885NSD2 122/4885BRD4 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.